http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
1-Phenylindole Ester류의 합성과 반응성 연구
崔舜圭,金兪瑛,兪丙國,李龍均,鄭大一 東亞大學校附設基礎科學硏究所 1993 基礎科學硏究論文集 Vol.10 No.1
일반적인 dienophile에 대한 pyrrole의 반응은 pyrrole이 diene system으로 작용된 [4+2] 고리부가반응과 pyrrole의 α-탄소 위치에 부가되는 Michael형태의 반응이 알려져 있다.
우순섭,장윤성,김태균,이영수,심광섭,유광희 한양대학교 의과대학 1999 한양의대 학술지 Vol.19 No.1
Recently many dentists would like to select the implant installation for the restoration of partially or fully edentulous patient. Usually, it is needed at least 8mm of alveolar bone height for implant installation. But, in many cases, the implant installation is impossible due to anatomic limitation such as maxillary sinus, floor of nose, mandibular canal, lack of width, etc. So, dentists must come over these limitations by methods of sinus lift, nerve repositioning, transmandibular implant etc. Especially, a lot of ridges have inadequate bone height at the upper molar edentulous areas, and to insert implant for such sites represents low success rate. So, autogenous or allogenic or alloplastic bone can be grafted before or at the same thme with implant installation. We report a case of 22 year-old woman who was performed implant installation successfully by using sinus lift technique with iliac block bone graft to a patient whose low alveolar bone height made common implantation impossible. Now, she exerts good occlusive function at the time of 15 months after the operation.
Clinical Impact of Exosomal microRNA in Liver Fibrosis: Based on Next-Generation Sequencing Analysis
( Young Chang ),( Jae-a Han ),( Suk Min Kang ),( Soung Won Jeong ),( Tom Ryu ),( Han Seul Park ),( Jeong-ju Yoo ),( Sae Hwan Lee ),( Sang Gyune Kim ),( Young Seok Kim ),( Hong Soo Kim ),( So Young Jin 대한간학회 2021 춘·추계 학술대회 (KASL) Vol.2021 No.1
Young Chang,Jun Il Kim,이보라,Sang Gyune Kim,정민정,Young Seok Kim,Soung Won Jeong,Jae Young Jang,Jeong-Ju Yoo 대한간학회 2020 Clinical and Molecular Hepatology(대한간학회지) Vol.26 No.3
Background/Aims: Liver biopsy (LB) remains the gold standard for the evaluation of liver disease. However, over the past two decades, many noninvasive tests have been developed and utilized in clinical practice as alternatives to LB. The aim of this study was to evaluate the clinical use and safety of LB in the era of noninvasive assessment of liver fibrosis. Methods: This retrospective study included 1,944 consecutive cases of LB performed between 2001 and 2018 in a tertiary hospital. All of the LBs were conducted under ultrasonography guidance with 18-gauge cutting needles. Results: LBs were performed an average of approximately 108 times per year during the study period. Chronic hepatitis B (25.3%) and suspected malignancy (20.5%) were the two most common indications for LB. The use of LB for nonalcoholic fatty liver disease increased from 8.1% to 17.2% in the past 5 years compared to the last 10 years, while that for viral hepatitis decreased from 40.3% to 18.9%. Discordance rate between the suspected diagnosis and the final diagnosis was 2.6% (51 cases). The overall rate of major adverse events was 0.05% (one case), which involved delayed bleeding at the biopsy site. Liver cirrhosis was observed in 563 cases (28.9%), and the presence of cirrhosis did not affect the frequency of complications (P=0.289). Conclusions: LB is widely used in clinical practice as an irreplaceable diagnostic tool, even in the era of noninvasiveness. Ultrasonography-guided LB can be performed safely in patients with liver cirrhosis.
Clinical Impact of Exosomal microRNA as a Novel Biomarker of Liver Fibrosis
( Young Chang ),( Jae-a Han ),( Suk Min Kang ),( Soung Won Jeong ),( Tom Ryu ),( Han Seul Park ),( Jeong-ju Yoo ),( Sae Hwan Lee ),( Sang Gyune Kim ),( Young Seok Kim ),( Hong Soo Kim ),( So Young Jin 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: Many approaches have been suggested for the non-invasive diagnosis of liver fibrosis, including the use of serum biomarkers and ultrasound-based elastography, but none has yet replaced liver biopsy. MicroRNAs (miRNAs) have been suggested as potential diagnostic tools for liver diseases. We investigated alterations in the expression of serum exosomal miRNAs with the progression of liver fibrosis and evaluated their clinical applicability as biomarkers. Methods: This study prospectively enrolled 71 patients who underwent liver biopsy at a large-volume academic hospital in Korea. Exosomes were extracted from serum samples, and next-generation sequencing (NGS) of miRNAs was conducted in patients from different stages of liver fibrosis. Differential expression of miRNAs was quantified using targeted real-time quantitative polymerase chain reaction (RT-qPCR). A model was derived to discriminate advanced fibrosis based on miRNA levels using multivariate logistic regression. The performance of this model was evaluated and compared using area under the receiver operator characteristic (ROC) curve (AUC) and De- Long’s test. Results: NGS data revealed the relationship between exosomal miR-122 expression and liver fibrosis progression. The level of miR-122 decreased as the pathologic fibrosis grade progressed from stage 0 to 4. Patients with biopsy-proven advanced fibrosis had significantly lower levels of exosomal miR-122 (P<0.001) than those without advanced fibrosis. Exosomal miR-122 exhibited a fair performance in discriminating advanced fibrosis with an AUC of 0.77, which improved to 0.86 in combination with fibrosis-4 score (FIB-4) and transient elastography (TE). This value was higher than that reported for any other non-invasive modalities, including TE (AUC of 0.80) or FIB-4 (AUC of 0.57) alone. In a subgroup of patients with a non-viral etiology of liver disease, the performance of exosomal miR-122 as a biomarker improved, evident from the increase in the AUC value to 0.87. In this subpopulation, the combination model of miR- 122, FIB-4, and TE showed the best discrimination ability (AUC of 0.90), which was significantly higher than that of TE alone (AUC of 0.83; DeLong’s test P=0.046). Inhibition of miR-122 expression increased the proliferation of the human hepatic stellate cell line, LX-2, and upregulated the expression of collagen- 1A, a-smooth muscle actin, fibronectin, and transforming growth factor-ß. Conclusions: Exosomal miR-122 may serve as a novel biomarker for discriminating advanced liver fibrosis, and its accuracy may enhanced in combination with other non-invasive tests such as FIB-4 and TE.
( Sang Gyune Kim ),( Jeong-ju Yoo ),( Young Seok Kim ),( Bora Lee ),( Soung Won Jeong ),( Jae Young Jang ),( Sae Hwan Lee ),( Hong Soo Kim ),( Young Don Kim ),( Gab Jin Cheon ),( Boo Sung Kim ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: To date, there is no acceptable criteria of spleen size for the clinical diagnosis of liver cirrhosis even though the recent Baveno consensus states splenomegaly is an adjunctive finding to define liver cirrhosis. We evaluated how relevant spleen volume (SV) measured by ultrasonography is to liver fibrosis stage and investigated the optimal cut-off of SV for liver cirrhosis. Methods: Total 431 patients whose SV was measured by ultrasonography (length x height x width x π/6) and got a liver biopsy for various reasons were included in this study. Spleen volume/body surface area (SV/BSA) in each patient was used for sensitivity analysis. Fibroscan score (kPa) was compared to SV for the relation with liver fibrosis stage. Clinical and laboratory findings were also collected. Results: The baseline characteristics of the patients were as follows: mean age (49.1±12.2), slightly male predominance (223/431, 51.7%), mean BSA (1.7±0.2 m2), most common etiology of liver disease is hepatitis B (190, 44.1%), mean MELD score (9.7±4.1), Child-Pugh class [(A/B/C, 339(78.7%)/75(17.4%)/17(3.9%)], fibrosis stage [F0/F1/F2/F3/F4, 35(8.1%)/40(9.3%)/69(16.0%)/56(12.99%)/231(53.6%)]. SV was significantly larger in young age (<40), male sex, viral hepatitis, high BSA, high MELD and Child-Pugh score. SV was also well correlated with fibroscan score (r=0.509, p<0.001). Mean SV (ml) according to fibrosis stage was F0 (169±59), F1 (189±99), F2 (198±82), F3 (236±79), F4 (457±283). AUROCs of SV and SV/SBA for predicting cirrhosis were 0.891 (95% confidence interval, 0.862-0.921), 0.905 (95% CI, 0.878-0.932). Optimal cut-off of SV and SV/SBA for the diagnosis of cirrhosis were 268ml, 161ml respectively. Conclusions: SV measured by ultrasonography was closely associated with severity of liver disease and fibrosis stage. SV measurement using ultrasonography is useful as a supplementary method for the diagnosis of liver cirrhosis.